Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drotrecogin alfa (activated) in septic shock
NCT00279214Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of drotrecogin alfa in septic shock and sepsis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Cumulative Vasopressor Index at 24 hours. Started Nov 2005; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on NCT00279214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00279214.